Have an account? Log in.
I don't have an account.
Natera rises after a Delaware court grants a 30% ongoing royalty in its MRD patent battle with ArcherDx and Invitae.
Natera Signatera data shows MRD-guided therapy may reduce surgery in older breast cancer patients; analysts maintain bullish outlook.
The Starter plan only unlocks analyses for the 25 stocks tracked over the past month. With the Compact plan, you get access to all stocks from Germany and the USA – with Premium, worldwide access.